Rare Disease Genetic Testing Market (By Disease Type: Neurological, CVDs; By Specialty: Molecular, Biochemical; By Technology: NGS, PCR-based; By End Use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Rare Disease Genetic Testing Market 

5.1. COVID-19 Landscape: Rare Disease Genetic Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Rare Disease Genetic Testing Market, By Disease Type

8.1. Rare Disease Genetic Testing Market, by Disease Type, 2022-2030

8.1.1. Neurological Disease

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Immunological Disorders

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Hematology Diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Endocrine & Metabolism Diseases

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Cancer

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Musculoskeletal Disorders

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Cardiovascular Disorders (CVDs)

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Dermatology Disease

8.1.8.1. Market Revenue and Forecast (2017-2030)

8.1.9. Others

8.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Rare Disease Genetic Testing Market, By Technology

9.1. Rare Disease Genetic Testing Market, by Technology e, 2022-2030

9.1.1. Next-Generation Sequencing (NGS)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Array Technology

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. PCR-based Testing

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. FISH

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Sanger Sequencing

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Karyotyping

9.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Rare Disease Genetic Testing Market, By Specialty 

10.1. Rare Disease Genetic Testing Market, by Specialty, 2022-2030

10.1.1. Molecular Genetic Tests

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Chromosomal Genetic Tests

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Biochemical Genetic Tests

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Rare Disease Genetic Testing Market, By End-Use 

11.1. Rare Disease Genetic Testing Market, by End-Use, 2022-2030

11.1.1. Research Laboratories & CROs

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Hospitals & Clinics

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Diagnostic Laboratories

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Rare Disease Genetic Testing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Technology (2017-2030)

12.1.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.1.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.1.5.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.1.6.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.2.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.2.5.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.2.6.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.2.7.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.2.8.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.3.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.3.5.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.3.6.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.3.7.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.3.8.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.4.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.4.5.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.4.6.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.4.7.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.4.8.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.5.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.5.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.5.5.4. Market Revenue and Forecast, by End-Use (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Specialty (2017-2030)

12.5.6.4. Market Revenue and Forecast, by End-Use (2017-2030)

Chapter 13. Company Profiles

13.1. Quest Diagnostics Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Centogene N.V.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Invitae Corp.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. 3billion, Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Arup Laboratories

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Eurofins Scientific

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Strand Life Sciences

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Ambry Genetics

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Perkin Elmer, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Realm IDX, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms